Nanobiotix shares fall 17% in one week, at the bottom of the SBF 120
The Paris-based oncology nanomedicine biotech continues its weekly decline in a market trending downward. The stock is moving clearly away from its medium-term benchmarks, while management has just completed two meetings with the financial community in London.
A 17% weekly decline that pushes the stock away from its moving averages
Nanobiotix shares closed down 2.51% at €24.08, after falling 5.5% on Monday and 17% over seven days. The stock had nonetheless gained nearly 26% over one month, and this October-November rebound is eroding session after session.
The stock is now below its 20-day moving average (€27.48, a gap of 12.4%), its 50-day moving average (€26.29, a gap of 8.4%) and its 200-day moving average (€29.85, a gap of 19.3%).
The RSI at 40 remains neutral, and the stock ranks in the lower part of the SBF 120 (the largest declines in the index were Alstom, Vusion and Valneva), while the index fell 0.82%. Support at €18.85 is still far away, and resistance at €30.36 is further still.
Cash of €110.9 million announced in September, funding through 2029
The fundamental benchmarks for the case remain those set at the publication of the first-half 2026 results on September 24. The company then indicated it held €110.9 million in cash, enough to fund its operations through 2029. Its NBTXR3 (JNJ-1900) radio-amplifier, combined with radiotherapy, is being developed in partnership with Johnson & Johnson.
On November 16 and 17, management addressed the financial community in London, at the Jefferies and UBS conferences. The stock is also listed on the Nasdaq under the symbol NBTX. Today's session comes amid a marked decline in the CAC 40 (-0.85%) and the SBF 120, against a backdrop of tensions in technology stocks.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.